Fig. 3: Nanoparticle in vitro activity and interaction with immune cells. | Nature Communications

Fig. 3: Nanoparticle in vitro activity and interaction with immune cells.

From: Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors

Fig. 3

a, b Dose-dependent response of TLR7 (a) and TLR8 (b) reporter cell lines after incubation with PNP, free R848, and PNP-R848 (n = 6, mean + SD). c, d Expression of CD80 (c) and CD86 (d) by bone marrow-derived cells (BMDCs) after incubation with free R848 or PNP-R848. e–g Dose-dependent secretion of IL-6 (e), TNFα (f), and IL-12p40 (g) by BMDCs after incubation with free R848 and PNP-R848 (n = 1 for (e) and n = 2 for (f and g)). h, i Quantification of binding (h) and uptake (i) of PEG-NP and PNP by immune cell subsets (CD45+, CD11b+, and CD11c+) after incubation with BMDCs in vitro (n = 4, mean + SD; MFI = mean fluorescence intensity). j–l In vivo uptake of PEG-NP and PNP by the total tumor cell population (j), CD45+ cells (k), and CD11c+ cells (l) at various timepoints after intratumoral administration (n = 4 for 1 h timepoint and n = 3 for rest of the timepoints, mean + SD). MFI was normalized based on the total cell number. Source data are provided as a Source Data file.

Back to article page